Read + Share
Amedeo Smart
Independent Medical Education
Cheng X, Liu P, Zhao Q, Ye L, et al. Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China. Eur J Obstet Gynecol Reprod Biol 2025;314:114707.PMID: 40967072
Email
LinkedIn
Privacy Policy